10x Genomics (TXG) – Research Analysts’ Recent Ratings Updates

10x Genomics (NASDAQ: TXG) has recently received a number of price target changes and ratings updates:

• 10/23/2026 – 10x Genomics was downgraded by Stephens from “overweight” to “equal weight”.
• 10/13/2026 – 10x Genomics was given a new $70.00 price target by Stifel Nicolaus.
• 10/13/2026 – 10x Genomics had its price target raised by TD Cowen from $47.00 to $70.00. They now have a “hold” rating on the stock.
• 10/12/2026 – 10x Genomics had its price target raised by Morgan Stanley from $40.00 to $70.00. They now have an “equal weight” rating on the stock.
• 10/12/2026 – 10x Genomics had its price target raised by Canaccord Genuity Group from $60.00 to $100.00. They now have a “buy” rating on the stock.
• 10/7/2026 – 10x Genomics had its price target raised by Barclays from $52.00 to $110.00. They now have an “overweight” rating on the stock.
• 9/29/2026 – 10x Genomics had its price target raised by Leerink Partners from $40.00 to $90.00. They now have a “market perform” rating on the stock.
• 9/28/2026 – 10x Genomics had its price target raised by Piper Sandler from $47.00 to $80.00. They now have a “neutral” rating on the stock.
• 9/28/2026 – 10x Genomics is now covered by Argus. They set a “buy” rating and a $110.00 price target on the stock.
• 9/21/2026 – 10x Genomics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/9/2026 – 10x Genomics is now covered by UBS Group. They set a “neutral” rating and a $68.00 price target on the stock.
• 9/1/2026 – 10x Genomics is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $70.00 price target on the stock.
• 9/1/2026 – 10x Genomics is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $70.00 price target on the stock.

Insiders Place Their Bets

In related news, insider Benjamin J. Hindson sold 13,818 shares of 10x Genomics stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $63.02, for a total transaction of $870,810.36. Following the transaction, the insider directly owned 488,182 shares of the company’s stock, valued at $30,765,229.64. The trade was a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Shehnaaz Suliman sold 5,723 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total transaction of $464,650.37. Following the completion of the sale, the director owned 23,792 shares in the company, valued at approximately $1,931,672.48. This trade represents a 19.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 179,333 shares of company stock valued at $11,810,070. 8.84% of the stock is currently owned by insiders.

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.